News | June 01, 2022
NATCO launches first generic version of Nexavar Tablets in the US
The product will be launched by NATCO's commercial partner Viatris.
The product will be launched by NATCO's commercial partner Viatris.
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Multiples is the first private equity (PE) investor in the company
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Subscribe To Our Newsletter & Stay Updated
